PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.99%
R&D change of 44.99% while GNPX maintains spending. Bruce Berkowitz would investigate effectiveness.
-4.08%
G&A reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
80.19%
Other expenses change of 80.19% while GNPX maintains costs. Bruce Berkowitz would investigate efficiency.
21.99%
Operating expenses change of 21.99% while GNPX maintains costs. Bruce Berkowitz would investigate control.
21.99%
Total costs change of 21.99% while GNPX maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
80.19%
D&A change of 80.19% while GNPX maintains D&A. Bruce Berkowitz would investigate efficiency.
32.89%
EBITDA change of 32.89% while GNPX is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
-21.99%
Operating income decline while GNPX shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
198.65%
Other expenses change of 198.65% while GNPX maintains costs. Bruce Berkowitz would investigate control.
32.68%
Income change of 32.68% while GNPX is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.68%
Income change of 32.68% while GNPX is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
32.51%
EPS change of 32.51% while GNPX is flat. Bruce Berkowitz would examine quality.
32.51%
Diluted EPS change of 32.51% while GNPX is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.